Oxford Biomedica plc disclosed that its non‑executive director and chair, Dr. Roch Doliveux, bought 20,250 ordinary shares at £5.05 per share on Tuesday, Sept. 23. The transaction, valued at £102,262.50, was reported in accordance with the EU Market Abuse Regulation.
Following the purchase, Dr. Doliveux’s stake in the company rose to 459,055 shares, representing 0.379% of Oxford Biomedica’s issued share capital.
Oxford Biomedica, listed on the London Stock Exchange under the ticker OXB, provides contract development and manufacturing services for cell and gene therapies.
